Mihael Polymeropoulos is President, Chief Executive Officer and Chairman of the Board of Vanda Pharmaceuticals Inc. (VNDA). The company reported total compensation of $3,851,468 for fiscal year 2025.
| Salary | $965,655 |
|---|---|
| Bonus | $0 |
| Stock awards | $2,007,000 |
| Option awards | $0 |
| Non-equity incentive plan | $834,326 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $44,487 |
| Total | $3,851,468 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Vanda Pharmaceuticals Inc. filed April 23, 2026, accession 0001628280-26-026893.
| Peer-group chief executive median | $7,684,554 |
|---|---|
| Difference from that median | $-3,833,085 |
| Percentile within the disclosed peer group | 29th |
| Peers with a disclosed figure | 13 |
Medians and percentiles are computed across the peer group Vanda Pharmaceuticals Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mihael Polymeropoulos this page | President, Chief Executive Officer and Chairman of the Board | $3,851,468 |
| Joakim Wijkstrom | Senior Vice President, Chief Marketing Officer | $1,457,528 |
| Timothy Williams | Senior Vice President, General Counsel and Secretary | $1,444,969 |
| Kevin Moran | Senior Vice President, Chief Financial Officer and Treasurer | $1,439,660 |
| Gunther Birznieks | Senior Vice President, Business Development | $1,415,471 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Vanda Pharmaceuticals Inc. compensation brief.
Mihael Polymeropoulos's compensation sits inside Vanda Pharmaceuticals Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.